Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Daiichi Sankyo
Farmers Insurance
Teva
Merck
Baxter
Colorcon
Deloitte
Chinese Patent Office

Generated: April 21, 2018

DrugPatentWatch Database Preview

FAMVIR Drug Profile

« Back to Dashboard

Which patents cover Famvir, and what generic alternatives are available?

Famvir is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in FAMVIR is famciclovir. There are eight drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the famciclovir profile page.
Drug patent expirations by year for FAMVIR
Synonyms for FAMVIR
(2-(acetyloxymethyl)-4-(2-aminopurin-9-yl)-butyl) acetate
[2-(acetoxymethyl)-4-(2-aminopurin-9-yl)butyl] acetate
[2-(acetyloxymethyl)-4-(2-aminopurin-9-yl)-butyl] acetate
[2-(acetyloxymethyl)-4-(2-aminopurin-9-yl)butyl] acetate
1,3-Propanediol, 2-(2-(2-amino-9H-purin-9-yl)ethyl)-, diacetate (ester)
1,3-Propanediol, 2-[2-(2-amino-9H-purin-9-yl)ethyl]-, 1,3-diacetate
1,3-propanediol, 2-[2-(2-amino-9H-purin-9-yl)ethyl]-, diacetate (ester)
104227-87-4
2-(2-(2-amino-9H-purin-9-yl)ethyl)-1,3-propanediol diacetate
2-(2-(2-Amino-9H-purin-9-yl)ethyl)-1,3-propanediol diacetate (ester)
2-(2-(2-AMINO-9H-PURIN-9-YL)ETHYL)-1,3-PROPANEDIOL DIACETATE ESTER
2-(2-(2-Amino-9H-purin-9-yl)ethyl)propane-1,3-diyl diacetate
2-(acetoxymethyl)-4-(2-amino-4,5-dihydro-9H-purin-9-yl)butyl acetate
2-[(acetyloxy)methyl]-4-(2-amino-9H-purin-9-yl)butyl acetate
2-[2-(2-amino-9H-purin-9-yl)ethyl]-1,3-propanediol diacetate
2-[2-(2-Amino-9H-purin-9-yl)ethyl]-1,3-propanediol diacetate (ester)
2-[2-(2-Amino-9H-purin-9-yl)ethyl]trimethylene diacetate;2-[2-(2-Amino-9H-purin-9-yl)ethyl]trimethylene diacetate
227F874
9-(4-acetoxy-3-(acetoxymethyl)but-1-yl)-2-aminopurine
9-(4-acetoxy-3-acetoxymethylbut-1-yl)-2-aminopurine
9-[4-acetoxy-3-(acetoxymethyl)but-1-yl]-2-aminopurine
9-[4-acetoxy-3-(acetoxymethyl)butyl]-2-amino-9h purine
A19583
AB0013893
AB00639952_09
AB00639952_10
AB00639952-06
AB00639952-08
AB07547
AB2000579
AC-8066
AC1L1FOB
Acetic acid 2-acetoxymethyl-4-(2-amino-purin-9-yl)-butyl ester
AJ-26674
AK-120
AK-82773
AKOS005556609
ALBB-027262
AN-8356
Anti-Farnesyl Rabbit pAb
ANW-58321
BC201648
Bio-0039
BRD-K45033733-001-02-3
BRL 42810
BRL-42810
BSPBio_003489
C14H19N5O4
CAS-104227-87-4
CCG-39277
CF0039
CHEBI:4974
CHEMBL880
CJ-23991
CPD000466375
CS-1357
CTK8B7737
D00317
D0VT8P
DB00426
Diacetyl 6-deoxy-9-(4-hydroxy-3-hydroxymethyl-but-1-yl)guanine
DR001425
DSSTox_CID_3038
DSSTox_GSID_23038
DSSTox_RID_76845
DTXSID0023038
F0842
famciclovir
Famciclovir (Famvir)
Famciclovir (JAN/USAN/INN)
Famciclovir [USAN:BAN:INN]
Famciclovir, >=98% (HPLC)
Famciclovir, pharmaceutical secondary standard; traceable to USP
Famciclovir, United States Pharmacopeia (USP) Reference Standard
Famciclovirum
Famciclovirum [INN-Latin]
famcivir
FAMCYCLOVIR
famtrex
Famvir (TN)
FCV
FT-0602549
GGXKWVWZWMLJEH-UHFFFAOYSA-N
HE291757
HE291758
HMS1922L09
HMS2051G22
HMS2090G10
HMS2093K12
HMS2232H09
HMS3262O08
HMS3370D14
HMS3393G22
HMS3656A04
HY-17426
I03-0096
I789
IN1338
J-001134
K-0411
KB-220353
KBio2_000946
KBio2_003514
KBio2_006082
KBio3_002709
KBioGR_001162
KBioSS_000946
KS-00000XOD
KS-5020
LS-120147
MCULE-6850246103
MFCD00866964
MLS000759505
MLS001424115
MLS006011896
MolPort-003-666-602
NC00156
NCGC00095133-01
NCGC00095133-02
NCGC00095133-03
NCGC00095133-04
NCGC00095133-06
NCGC00261478-01
NSC-758921
NSC758921
Oravir
Pharmakon1600-01505201
QIC03ANI02
RT-012693
s2467
SAM001246732
SBI-0206743.P001
SC-43883
SCHEMBL2949
SMR000466375
SPBio_001202
Spectrum_000466
SPECTRUM1505201
Spectrum2_001101
Spectrum3_001675
Spectrum4_000611
Spectrum5_001548
STK623204
Tox21_111442
Tox21_111442_1
Tox21_500793
UNII-QIC03ANI02
ZINC1530635

US Patents and Regulatory Information for FAMVIR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis FAMVIR famciclovir TABLET;ORAL 020363-003 Dec 11, 1995 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Novartis FAMVIR famciclovir TABLET;ORAL 020363-001 Apr 26, 1996 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Novartis FAMVIR famciclovir TABLET;ORAL 020363-002 Jun 29, 1994 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for FAMVIR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis FAMVIR famciclovir TABLET;ORAL 020363-003 Dec 11, 1995 ➤ Try a Free Trial ➤ Try a Free Trial
Novartis FAMVIR famciclovir TABLET;ORAL 020363-003 Dec 11, 1995 ➤ Try a Free Trial ➤ Try a Free Trial
Novartis FAMVIR famciclovir TABLET;ORAL 020363-003 Dec 11, 1995 ➤ Try a Free Trial ➤ Try a Free Trial
Novartis FAMVIR famciclovir TABLET;ORAL 020363-003 Dec 11, 1995 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for FAMVIR
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Tablets 125 mg, 250 mg and 500 mg ➤ Subscribe 2004-12-28

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
US Army
Fish and Richardson
Cerilliant
Moodys
McKinsey
Teva
Colorcon
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.